RxDoctor Payments Data
★ My doctorsLook up a doctor →

Rajendra Makkar, MD

Interventional Cardiology · West Hollywood, CANPI 1164450235

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $84,514 of the $122,505 with a category attached, or 69.0%. 20 manufacturers reported payments, led by Edwards Lifesciences at 58.0% of the total. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$122,505in general payments, 2019–2025

Across 659 payments — averaging $185.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$71K
  • Boston Scientific$28K
  • Abbott$8K
  • Medtronic$7K
  • Daiichi Sankyo Inc.$4K
  • Jenavalve Technology, Inc.$2K
  • plus $3K from 14 others
$16,438,610in research payments, 2019–2025

Across 635 payments — averaging $25,888 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$8.9M
  • Boston Scientific$5.6M
  • Abbott$1.4M
  • Medtronic$356K
  • Bayer$79K
  • Biosense Webster, Inc.$32K
  • plus $9K from 2 others
$12,000in ownership & investment interests, 2019–2025

Across 1 payment — averaging $12,000 each. An ownership or investment interest held by the physician or an immediate family member.

  • Pi-cardia, Inc.$12K

What the payments were for

  • Consulting fees$1,8602%
  • Speaking & faculty fees$5000%
  • Grants$550%
  • Travel & lodging$84,51469%
  • Food & beverage$35,49229%
  • Education$840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Edwards Lifesciences458$71,038
Boston Scientific69$27,535
Abbott80$8,133
Medtronic(2 entities)18$6,617
Daiichi Sankyo Inc.1$4,334
Jenavalve Technology, Inc.8$2,115
Cathworks, Inc.2$585
Pi-cardia, Inc.3$499
Abiomed5$413
Shockwave Medical, Inc3$346
Penumbra, Inc.1$235
Siemens Medical Solutions USA, Inc.1$191
GE HealthCare1$146
Philips North America LLC3$86
Biotronik Inc.1$64
Nuwellis, Inc.1$62
Acist Medical Systems, Inc.1$37
Recor Medical Inc1$34
Heartflow, Inc.1$23
W. L. Gore & Associates, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$122,505 in reported general payments places this provider in the 90th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California →

Medicare billing

Part B allowed, 2024
$1,025,969
Medicare patients
999
Services billed
1,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate33$452

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in West Hollywood

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →